Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia

NCT04508075 is registered in ClinicalTrials.gov with PT Bio Farma as lead sponsor.

NCT NCT04508075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04508075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia
Lead sponsor
PT Bio Farma
Phase
Phase 3
Overall status
Completed
Start date
August 10, 2020
Completion date
August 31, 2021
Enrollment
1,620 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov2 infection